Imatinib and beyond—the new CML study IVA randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia

被引：0
|
作者：
U. Berger
G. Engelich
A. Reiter
A. Hochhaus
R. Hehlmann
机构：
[1] Universität Heidelberg,III. Medizinische Universitätsklinik, Klinikum Mannheim
来源：
Annals of Hematology | 2004年 / 83卷
关键词：
Chronic myeloid leukemia; Clinical trial; Imatinib; Interferon alpha; Stem cell transplantation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：258 / 264
页数：6
相关论文
共 50 条
  • [21] Depletion of circulating plasmacytoid dendritic cells in chronic myelogenous leukemia and their restoration after interferon-alpha or imatinib mesylate.
    Rossignol, Alexis
    Barra, Anne
    Roy, Lydia
    Guilhot, Francois
    Turhan, Ali G.
    Gombert, Jean-Marc
    BLOOD, 2006, 108 (11) : 625A - 625A
  • [22] BOSUTINIB (BOS) VS IMATINIB (IM) FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML): INITIAL RESULTS FROM THE BFORE TRIAL
    Gambacorti-Passerini, C.
    Deininger, M.
    Mauro, M. J.
    Chuah, C.
    Kim, D. -W.
    Reilly, L.
    Jeynes-Ellis, A.
    Leip, E.
    Bardy-Bouxin, N.
    Hochhaus, A.
    Bruemmendorf, T. H.
    Cortes, J. E.
    HAEMATOLOGICA, 2017, 102 : 20 - 20
  • [23] Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up
    Gambacorti-Passerini, Carlo
    Deininger, Michael W.
    Mauro, Michael J.
    Chuah, Charles
    Kim, Dong-Wook
    Dyagil, Iryna
    Glushko, Natalia
    Milojkovic, Dragana
    le Coutre, Philipp D.
    Gutierrez, Valentin Garcia
    Crescenzo, Rocco J.
    Leip, Eric
    Bardy-Bouxin, Nathalie
    Hochhaus, Andrea
    Brummendorf, Timothy H.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [24] Bosutinib (BOS) vs Imatinib (IM) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Initial Results from the BFORE Trial
    Cortes, Jorge
    Gambacorti-Passerini, Carlo
    Deininger, Michael
    Mauro, Michael
    Chuah, Charles
    Kim, Dong Wook
    Reilly, Laurence
    Jeynes-Ellis, Alison
    Leip, Eric
    Bardy-Bouxin, Nathalie
    Hochhaus, Andreas
    Brummendorf, Tim
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S316 - S316
  • [25] Bosutinib (BOS) vs imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): initial results from the bfore trial
    Bruemmendorf, T. H.
    Gambacorti-Passerini, C.
    Deininger, M.
    Mauro, M. J.
    Chuah, C.
    Kim, D. -W.
    Le Coutre, P.
    Jentsch-Ullrich, K.
    Waller, C.
    Wolf, D.
    Reilly, L.
    Jeynes-Ellis, A.
    Leip, E.
    Bardy-Bouxin, N.
    Hochhaus, A.
    Cortes, J. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 121 - 121
  • [26] Use of RT-PCR to monitor the possible benefit of adding interferon-alpha to imatinib for patients with CML in chronic phase.
    Burton, CH
    Avery, S
    Ranger, A
    Nadal, E
    Nathan, I
    Olavarria, E
    Apperley, JF
    Goldman, JM
    Marin, D
    BLOOD, 2003, 102 (11) : 908A - 908A
  • [27] Dasatinib vs imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): DASISION European subpopulation analysis
    Stegelmann, F.
    Mayer, J.
    Warzocha, K.
    Huguet, F.
    Steegmann, J. L.
    Gambacorti-Passerini, C.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    ONKOLOGIE, 2012, 35 : 47 - 48
  • [28] Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial
    Deininger, Michael W.
    Kota, Vamsi
    Lipton, Jeff H.
    Milojkovic, Dragana
    Garcia Gutierrez, Valentin
    Leip, Eric
    Nick, Sonja
    Hochhaus, Andreas
    Gambacorti-Passerini, Carlo
    Cortes, Jorge E.
    Brummendorf, Tim H.
    BLOOD, 2018, 132
  • [29] A Phase 2 study of the Combination of Omacetaxine and Imatinib in the Treatment of Patients with Chronic Myeloid Leukemia (CML) in Advanced Stages or After Failure to Imatinib.
    Ayoubi, Mohamad
    Kantarjian, Hagop M.
    Wierda, William
    Ferrajoli, Alessandra
    Hiteshew, Jody
    Estrov, Zeev
    Cortes-Franco, Jorge
    BLOOD, 2009, 114 (22) : 862 - 863
  • [30] Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
    Cortes, Jorge E.
    Jiang, Qian
    Wang, Jianxiang
    Weng, Jianyu
    Zhu, Huanling
    Liu, Xiaoli
    Hochhaus, Andreas
    Kim, Dong-Wook
    Radich, Jerald
    Savona, Michael
    Martin-Regueira, Patricia
    Sy, Oumar
    Gurnani, Renuka
    Saglio, Giuseppe
    LEUKEMIA, 2020, 34 (08) : 2064 - 2073
12345